v3.26.1
Restatement of Previously Issued Quarterly Financial Statements - Schedule of Restated Consolidated Statement of Cash Flows (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2024
Mar. 31, 2025
Jun. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Schedule of Restated Audited Consolidated Statement of Cash Flows [Line Items]          
Net loss $ (29,565) [1] $ (30,137) [1] $ (31,827) [1] $ (49,182) $ (1,368)
Change in fair value of warrant liability 25,965 21,837 22,123 34,172 (7,587)
Issuance costs related to warrants   189 189 189 690
Inventory (188) (73) (3) (96) (207)
Stock based compensation 1,444 3,077 3,429 3,724
Depreciation and amortization 281 505 941 1,387 98
Accounts receivable   (227) [1]   422 (4,218)
Accrued expenses   (88) [1]   1,280 (82)
Net cash used in operating activities (2,358) [1] (4,937) [1] (5,409) [1] (8,911) (4,941)
Purchase of property and equipment (138) (386) (4,839) (5,144) (844)
Purchase of intangible assets     (84) [1] (590) (5,471)
Purchase of long-term investments     (142) [1] (102) 730
Net cash used in investing activities (440) [1] (15,335) [1] (41,741) [1] (56,183) (22,851)
Payment of issuance cost of ordinary shares   (1,180) (1,180)    
Proceeds from Warrant Exercises     18,038 18,909
Contributions from Non-controlling Interests [1]        
Proceeds from issuance of ordinary shares 8,063 18,038 48,650 219,808 30,182
Net Cash provided by financing activities 8,059 [1] 16,832 [1] 65,477 [1] 236,102 41,925
Allowance for credit loss [1]   (94)      
As Previously Reported [Member]          
Schedule of Restated Audited Consolidated Statement of Cash Flows [Line Items]          
Net loss (3,548) [1] (8,126) [1] (12,238) [1] (15,754) (8,140)
Change in fair value of warrant liability    
Issuance costs related to warrants      
Inventory (248) (343) (334) (232) (326)
Stock based compensation    
Depreciation and amortization 513 730 1,635 2,319 81
Accounts receivable   (321) [1]   421  
Accrued expenses   (91) [1]     38
Net cash used in operating activities (3,578) [1] (8,076) [1] (11,197) [1] (9,043) (5,060)
Purchase of property and equipment (78) (116) (4,509) (5,009) (725)
Purchase of intangible assets     (100) [1] (591) (5,470)
Purchase of long-term investments [1]     (247)    
Net cash used in investing activities (380) [1] (15,130) [1] (41,532) [1] (47,996) (22,731)
Payment of issuance cost of ordinary shares   0    
Proceeds from Warrant Exercises        
Contributions from Non-controlling Interests [1] (21)        
Proceeds from issuance of ordinary shares 9,244 19,792 71,087    
Net Cash provided by financing activities 9,219 [1] 19,766 [1] 71,056 [1]   41,923
Allowance for credit loss [1]        
Restatement Adjustment [Member]          
Schedule of Restated Audited Consolidated Statement of Cash Flows [Line Items]          
Net loss (26,017) [1] (22,011) [1] (19,591) [1] (33,428) 6,772
Change in fair value of warrant liability 25,965 21,837 22,123    
Issuance costs related to warrants   189 189    
Inventory 60 270 331 136 119
Stock based compensation 1,444 3,077 3,429    
Depreciation and amortization (232) (225) (694) (932) 17
Accounts receivable   94 [1]   1  
Accrued expenses   3 [1]     (120)
Net cash used in operating activities 1,220 [1] 3,139 [1] 5,788 [1] 132 119
Purchase of property and equipment (60) (270) (330) (135) (119)
Purchase of intangible assets     16 [1] 1 (1)
Purchase of long-term investments [1]     105    
Net cash used in investing activities (60) [1] (205) [1] (209) [1] $ (8,187) (120)
Payment of issuance cost of ordinary shares   (1,180) (1,180)    
Proceeds from Warrant Exercises     18,038    
Contributions from Non-controlling Interests [1] 21        
Proceeds from issuance of ordinary shares (1,181) (1,754) (22,437)    
Net Cash provided by financing activities $ (1,160) [1] (2,934) [1] $ (5,579) [1]   $ 2
Allowance for credit loss [1]   $ (94)      
[1] Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.